BRISBANE, Calif., April 26, 2024 Tempest Therapeutics, Inc. , a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today.
BRISBANE, Calif., April 09, 2024 Tempest Therapeutics, Inc. , a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today.
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.